Targeted Oncology· @TargetedOnc · X·· 23 hours agoScore70
Body · original
KEYNOTE-B49 highlights an important distinction:
A statistically significant PFS HR does not necessarily translate into a large median PFS gain or improved survival.
How should we weigh the full survival curves, absolute benefit, toxicity and patient experience?
#ESMO26
45 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA51matched by Proffered paper 2: Breast cancer, early and advanced stage
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.orgSource: Targeted Oncology · x.com